BPC-157 is a 15-residue synthetic peptide whose sequence was taken from a larger protein described in gastric juice, which is where the name “body protection compound” comes from. Since the early 1990s it has been studied in hundreds of rodent and cell-culture experiments, mostly by one research group in Zagreb, Croatia, and it has become one of the most frequently searched research peptides.
That popularity has run well ahead of the evidence. The sections below set out what the published work actually covers: where the peptide came from, which signaling pathways have been examined, the main model systems, and the clear limits of a literature that remains almost entirely preclinical.
At a glance
- Class: Synthetic pentadecapeptide (15 amino acids)
- Origin: Partial sequence of a gastric juice protein; developed and characterized by Predrag Sikiric’s group at the University of Zagreb from the early 1990s
- Structure: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val; C62H98N16O22; 1419.5 g/mol; CAS 137525-51-0
- Main research areas: tendon and fibroblast biology, angiogenesis and vascular injury, wound models, the gut-brain axis
- Regulatory status: Not FDA approved for any use; on the WADA Prohibited List under S0 since 2022
Structure and origin
The Sikiric group reported isolating a protein fraction from human gastric juice that appeared to protect the stomach lining in rat models. BPC-157 is a short partial sequence of that material, made by solid-phase synthesis rather than extracted. In the group’s early papers it was described as stable in gastric juice, a property that set it apart from many peptides and shaped its use in oral and gastrointestinal experiments.
Structurally, the chain is notable for a run of three prolines near the N-terminus and a total of four prolines overall. Proline-rich segments resist many proteases and restrict backbone flexibility, which is one proposed explanation for the peptide’s reported stability. Two adjacent aspartic acids and one glutamic acid give it a net negative charge at neutral pH. There is no disulfide bond, no cyclization and no non-natural residue; it is a linear peptide of standard L-amino acids.
Mechanism: what the research shows
No dedicated receptor for BPC-157 has been identified. Instead, studies have tracked downstream signaling changes in specific cell types, and three pathways come up repeatedly.
The first is focal adhesion signaling. In cultured rat Achilles tendon fibroblasts, BPC-157 exposure was associated with increased phosphorylation of focal adhesion kinase (FAK) and paxillin, along with greater cell spreading and migration in scratch and transwell assays (Chang et al., 2011). The same work reported better fibroblast survival under hydrogen peroxide stress.
The second is VEGF receptor signaling. In human umbilical vein endothelial cells (HUVECs), BPC-157 was linked to activation and increased expression of VEGFR2 and to downstream Akt and eNOS signaling, and the authors connected this to vessel formation in a rat hindlimb ischemia model (Hsieh et al., 2017). An earlier study likewise reported HUVEC proliferation, migration and tube formation in vitro alongside wound-closure measurements in an alkali-burn model in rats (Huang et al., 2015).
The third is the nitric oxide system. Reviews from the originating group describe interactions with NO synthesis in several vascular injury and thrombosis models, interpreted as a modulating effect rather than simple stimulation or blockade (Seiwerth et al., 2014).
Key areas of study
Tendon and ligament models
Tendon work has the most mechanistic detail. Rat Achilles tendon explants placed in culture with the peptide showed greater fibroblast outgrowth, and isolated tendon fibroblasts showed the FAK-paxillin changes noted above (Chang et al., 2011). These experiments are useful because they combine tissue-level and cell-level readouts, but they remain small, single-lab rodent studies.
Angiogenesis and vascular biology
Endothelial cell assays are the second major thread. The VEGFR2 findings in HUVECs and the hindlimb ischemia data (Hsieh et al., 2017) are among the few BPC-157 results that name a specific receptor-level event, which is why they are often cited in discussions of mechanism. A review of vascular studies covers occlusion, bleeding and thrombosis models in rats (Seiwerth et al., 2014).
Wound models
In a rat alkali-burn model, researchers measured wound closure, re-epithelialization, granulation tissue and collagen deposition, and paired those readouts with endothelial assays in vitro (Huang et al., 2015). Burn and incision models are standard in repair research, and this study is one of the more detailed BPC-157 papers from outside the Zagreb group.
The gut-brain axis
Given its gastric origin, much early work used gastrointestinal lesion models. The Sikiric group has since proposed that BPC-157 acts along the gut-brain axis, reviewing rodent experiments that involve dopamine and serotonin systems as well as gastrointestinal endpoints (Sikiric et al., 2016). This is a broad theoretical framework built mainly on the group’s own studies.
What the evidence does not show
A 2025 systematic review of BPC-157 in orthopaedic and sports medicine concluded that the evidence base is almost entirely preclinical and reported that no clinical safety data were found (Vasireddi et al., 2025). Several further points are worth stating plainly:
- A large share of all BPC-157 papers come from a single research group, and independent replication is limited.
- Most studies are small rodent experiments with short follow-up, and many use different models, routes and endpoints, which makes results hard to pool.
- No specific receptor has been identified, so the mechanism is described through downstream markers that many other compounds also affect.
- There are no published, adequately sized controlled trials in humans, and no regulator has approved BPC-157 for any use.
Rodent and cell data can generate hypotheses. They do not establish safety or effects in people.
Regulatory status
BPC-157 is not approved by the FDA for any use. The World Anti-Doping Agency has listed it under S0 (non-approved substances) on the Prohibited List since 2022. Rogue Compounds sells it as a research reagent only.
Handling and storage in the lab
As a lyophilized peptide, BPC-157 should be kept sealed and refrigerated at 2–8°C (36–46°F), protected from light, until use.
Sourcing and documentation
Rogue Compounds has BPC-157 made in small batches. Every vial carries a batch number and a QR code that opens the independent U.S. testing lab’s own report for that batch. The same batch COA is posted on the product page and in the COA Library.
View BPC-157 on Rogue Compounds
References
- Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. PMID 21030672
- Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. PMID 27847966
- Huang T, et al. Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro. Drug Des Devel Ther. 2015;9:2485-2499. PMID 25995620
- Seiwerth S, et al. BPC 157 and blood vessels. Curr Pharm Des. 2014;20(7):1121-1125. PMID 23782145
- Sikiric P, et al. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Curr Neuropharmacol. 2016;14(8):857-865. PMID 27138887
- Vasireddi N, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025;21(4):485-495. PMID 40756949
Research use only. Rogue Compounds products are sold strictly for laboratory research. They are not for human or veterinary use, and nothing in this article is medical advice. The studies cited here describe published research, not this product or any use of it.